A5012147704- Chronic Lymphocytic Leukemia Research
- PI3K/AKT/mTOR signaling in cancer
- Acute Lymphoblastic Leukemia research
- Advanced Breast Cancer Therapies
University of North Carolina at Chapel Hill
2022-2024
UNC Lineberger Comprehensive Cancer Center
2022
Abstract Venetoclax is a first‐in‐class orally administered B‐cell lymphoma‐2 inhibitor used to treat chronic lymphocytic leukemia (CLL). primarily metabolized in the liver by cytochrome P450 (CYP) 3A4 its major metabolite M27, via M5, and M2, M3, M4 oxidation. Although venetoclax breakthrough CLL treatment, managing drug safety toxicity remains clinical challenge. The objectives of this study were investigate how individual CYP3A activity protein expression affect hepatic metabolism vitro...
Background: Treatment (tx) options for patients (pts) with chronic/small lymphocytic leukemia (CLL/SLL) have expanded following regulatory approval of targeted agents. However, real-world evidence regarding pt outcomes and tx sequences is evolving. Aims: We assessed trends, the introduction Methods: The CLL Collaborative Study Real-World Evidence (CORE), a retrospective, international, observational study (23 centers) CLL/SLL pts provided data this analysis. Pts were diagnosed CLL/SLL,...
Background: Covalent Bruton Tyrosine Kinase (BTK) inhibitors (BTKi) have transformed the management of patients with chronic lymphocytic leukemia/small lymphoma (CLL/SLL), but these treatments are not curative and many will require additional treatment. BTKi share pharmacologic liabilities (e.g. low oral bioavailability, short half-life) that collectively may lead to suboptimal BTK target coverage especially in rapidly proliferating tumors high protein turnover such as accelerating CLL/SLL,...